Biotech entity
All 1 tracked stories fall under one category: clinical-trial. TLX591 is most often covered alongside Novartis, which appears in 1 of these 1 story. TLX591 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 4 original sources each.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. TLX591 is most often covered alongside Novartis, which appears in 1 of these 1 story. TLX591 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TLX591. Shared-story counts are live from our verified record — not editorial picks.
Part 2 Expansion
Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
Primary Objectives Met
Telix announces Part 1 achieved all primary safety and dosimetry goals.
Part 1 Completion
Enrollment for the safety and dosimetry portion of the study concludes.
Trial Initiation
ProstACT GLOBAL Phase 3 study begins enrollment.
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
TLX591 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
